KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?
Journal of Clinical Oncology · 10.10.2025 · 43 (29) · 3141-3143
DOI: 10.1200/jco-25-01439 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2025. Verfasst von David H Ilson. Beteiligte Einrichtung: Memorial Sloan Kettering Cancer Center, New York, NY. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
In the article that accompanies this editorial, the KEYNOTE-585 trial demonstrated that adding pembrolizumab to perioperative chemotherapy with 5-FU and cisplatin in resectable esophagogastric cancer improved pathologic complete response rate but did not significantly improve event free survival over chemotherapy alone, despite trends toward improvement in both event free and overall survival. Although a negative trial, results from KEYNOTE-585 support and reinforce the positive results recently reported from the MATTERHORN Trial, which establishes a new care standard adding durvalumab to perioperative FLOT chemotherapy in resectable esophagogastric cancer.
Autor:innen und Institutionen
- Memorial Sloan Kettering Cancer Center, New York, NY.
Förderung
- NCI NIH HHS
Zitieren
APA
Ilson, D. H. (2025). KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?. Journal of Clinical Oncology, 43(29), 3141-3143. https://doi.org/10.1200/jco-25-01439
Vancouver
Ilson DH. KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?. Journal of Clinical Oncology. 2025;43(29):3141-3143. doi:10.1200/jco-25-01439
BibTeX
@article{Ilson2025,
author = {Ilson, David H},
title = {KEYNOTE-585 Fails While Matterhorn Succeeds in Gastric Cancer: What Lessons Can We Learn?},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {29},
pages = {3141--3143},
doi = {10.1200/jco-25-01439}
}
EUVIMED